W. Brian Gibler, MD, FACEP, FACC, FAHA
Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP; Gregory J. Fermann, MD; Natalie Kreitzer, MD, MS
In this podcast, experts in Emergency Medicine, Pharmacy, and Neurocritical Care describe important real world data which emphasize the use of specific reversal therapy for patients with life-threatening bleeding in the anticoagulated patient. These large retrospective trials describe patient care in multiple hospitals with large numbers of patients. For patients with Factor Xa-associated bleeding, real world evidence indicates that specific reversal using andexanet alfa is superior to nonspecific repletion therapy. Decreased mortality is associated with this specific reversal therapy. The clinician needs to use both clinical trial data and real world data to provide optimal patient care for the anticoagulated patient with life-threatening bleeding.